HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $7
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on Unicycive Therapeutics (NASDAQ:UNCY) but lowers the price target from $8 to $7.

June 30, 2023 | 10:17 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Unicycive Therapeutics' price target has been lowered from $8 to $7 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target could potentially indicate a less optimistic outlook for the company's stock, which may negatively impact investor sentiment. However, the maintained 'Buy' rating suggests that the analyst still sees potential in the stock, which could balance out any negative impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100